Guna Pain Management

Dosage for Achillea Millefolium Whole is highly individualized and must be determined by an allergy specialist based on the patient's sensitivity level. There is no 'standard' dose, but therapy generally follows two phases:

Build-up Phase (Induction)

During this phase, the patient receives injections once or twice a week. The starting dose is usually very low (e.g., 0.05 mL of a 1:100,000 w/v dilution). The volume and concentration are gradually increased according to the patient's tolerance. A typical progression might involve moving from 1:10,000 to 1:1,000, and finally to 1:100 dilutions over several months.

Maintenance Phase

Once the 'top dose' or maximum tolerated dose is reached, the frequency of injections is decreased to once every 2 to 4 weeks. The maintenance dose is intended to sustain the immunological tolerance achieved during the build-up phase. This phase typically continues for 3 to 5 years.

Achillea Millefolium Whole extracts may be used in children, generally starting at age 5 or older. The dosing schedule is similar to that of adults, but healthcare providers exercise extreme caution due to the difficulty younger children may have in communicating early symptoms of a systemic reaction. Dosage is based on clinical response and skin test reactivity rather than body weight.

Renal Impairment

No specific dosage adjustments are typically required for renal impairment, as the systemic load of the protein extract is minimal. However, the patient's overall health should be stable before administration.

Hepatic Impairment

No dosage adjustments are defined for hepatic impairment. The metabolism of the extract occurs via local and systemic proteolysis rather than hepatic CYP450 pathways.

Elderly Patients

Geriatric patients may require more cautious dosing, particularly if they have underlying cardiovascular disease. The risk-benefit ratio must be carefully considered because elderly patients may be less able to tolerate the physiological stress of a systemic reaction or the administration of epinephrine.

• Clinical Setting Only: This medication must NEVER be self-administered. It must be given in a medical facility equipped with emergency supplies, including epinephrine, oxygen, and IV fluids.
• Injection Site: Administered subcutaneously (just under the skin), usually in the posterior aspect of the upper arm. The site should be rotated between injections.
• Observation Period: Patients MUST remain in the doctor's office for at least 30 minutes following an injection to monitor for signs of anaphylaxis.
• Storage: The extract should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose is missed, the next dose may need to be reduced depending on how much time has passed.

• 1-2 weeks late: The previous dose may be repeated.
• 3-4 weeks late: The dose is typically reduced by one or two increments.
• Over 4 weeks late: The healthcare provider may need to restart the build-up from a significantly lower concentration to ensure safety.

An 'overdose' in the context of allergenic extracts refers to an injection of a concentration higher than what the patient's immune system can currently tolerate. Signs include:

• Rapid onset of hives (urticaria)
• Swelling of the throat or tongue
• Difficulty breathing or wheezing
• Rapid drop in blood pressure (shock)

In the event of an overdose or systemic reaction, emergency protocols for anaphylaxis must be initiated immediately, typically involving the administration of intramuscular epinephrine.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency without medical guidance.

Most patients undergoing immunotherapy with Achillea Millefolium Whole will experience local reactions. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): Redness at the injection site that usually appears within minutes and may last for several hours.
• Swelling (Edema): A raised bump or 'wheal' at the site. If the swelling is larger than a half-dollar (approx. 3 cm), your doctor may adjust your next dose.
• Itching (Pruritus): Intense itching at the injection site is very common.
• Warmth: The skin around the injection site may feel warm to the touch.

These reactions are more widespread but usually manageable:

• Fatigue: Some patients feel unusually tired for a few hours after their injection.
• Headache: Mild to moderate tension-type headaches.
• Increased Allergy Symptoms: A temporary 'flare' of hay fever symptoms, such as sneezing, runny nose, or itchy eyes, shortly after the injection.
• Local Nodules: Small, hard lumps under the skin at the injection site that may persist for a few weeks.

• Generalized Urticaria: Hives appearing on parts of the body far from the injection site.
• Angioedema: Significant swelling of the lips, eyelids, or face.
• Persistent Cough: A dry, hacking cough that begins shortly after administration.
• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit).

> Warning: Stop taking Achillea Millefolium Whole and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Wheezing or Chest Tightness: This indicates bronchospasm (narrowing of the airways).
• Throat Constriction: A feeling that the throat is closing or difficulty swallowing.
• Hypotension: Feeling faint, dizzy, or passing out due to a sudden drop in blood pressure.
• Cyanosis: A bluish tint to the lips or fingernails, indicating low oxygen levels.
• Rapid Pulse: A racing heart accompanied by a sense of 'impending doom.'
• Nausea and Vomiting: Sudden gastrointestinal distress can be a sign of a systemic allergic reaction.

The long-term use of Achillea Millefolium Whole is generally associated with a reduction in allergy symptoms and a decreased risk of developing new allergies or asthma. However, some patients may develop 'Arthus-type' reactions—delayed local swelling and pain that occurs 6 to 12 hours after injection—due to the formation of immune complexes. This is usually managed by adjusting the dose or the interval between injections.

Most allergenic extracts, including Achillea Millefolium Whole, carry a class-wide warning regarding the risk of severe systemic reactions.

Summary of Warning: This product can cause severe life-threatening systemic reactions, including anaphylaxis. It must only be administered by healthcare providers prepared to manage such reactions. Patients with unstable asthma are at higher risk for severe outcomes. Certain medications, like beta-blockers, may make a patient less responsive to the usual doses of epinephrine used to treat a reaction.

Report any unusual symptoms to your healthcare provider, especially those occurring within the first few hours after an injection.

Achillea Millefolium Whole is a potent biological agent. Its safety depends heavily on the expertise of the administering clinician and the stability of the patient's health at the time of the injection. Patients should always inform their doctor if they are feeling unwell, have a fever, or are experiencing an exacerbation of asthma symptoms before receiving their dose.

No FDA black box warnings specifically unique to Achillea Millefolium Whole exist beyond the standard class-wide warnings for allergenic extracts. The primary concern is the risk of anaphylaxis, which is a sudden, systemic, and potentially fatal allergic reaction. Because of this risk, the extract is never used in home settings and requires a mandatory observation period post-administration.

• Allergic Reactions / Anaphylaxis Risk: This is the most significant risk. Reactions can occur even in patients who have tolerated previous injections for years. The risk is higher during the build-up phase and during peak pollen seasons.
• Asthma Status: Patients with symptomatic or poorly controlled asthma (FEV1 < 80% of predicted) should not receive immunotherapy injections. An injection given during an asthma flare can trigger a life-threatening bronchospasm.
• Cardiovascular Disease: Patients with significant heart disease may be at higher risk if a systemic reaction occurs, as their bodies are less able to compensate for the stress of anaphylaxis or the side effects of emergency epinephrine.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine, making it difficult to treat a systemic reaction if one occurs.

• Pre-Injection Assessment: The clinician will check for current allergy or asthma symptoms and may perform a peak flow meter test.
• 30-Minute Wait: A strict 30-minute observation period is required after every injection.
• Site Inspection: The injection site is inspected for large local reactions before the patient is allowed to leave.
• Long-term Review: Periodic re-evaluation of skin test reactivity or symptom scores is conducted to determine the continued necessity of treatment.

Most patients can drive after their 30-minute observation period. However, if you experience dizziness, fatigue, or 'brain fog' following an injection, you should avoid driving or operating heavy machinery until these symptoms resolve.

Alcohol consumption should be avoided for several hours before and after an injection. Alcohol causes vasodilation (widening of the blood vessels), which can theoretically increase the speed at which the allergen is absorbed into the bloodstream, potentially increasing the risk of a systemic reaction.

Immunotherapy is usually discontinued if:

1. 1The patient experiences a severe, life-threatening systemic reaction.
2. 2There is no clinical improvement after 12-24 months of maintenance therapy.
3. 3The patient becomes unable to comply with the required visit schedule.

> Important: Discuss all your medical conditions with your healthcare provider before starting Achillea Millefolium Whole.

While there are few absolute contraindications for drug-drug interactions with Achillea Millefolium Whole, certain combinations are avoided due to safety risks:

• Beta-Adrenergic Blockers (Beta-Blockers): Medications like propranolol, atenolol, or timolol (including eye drops) are generally contraindicated. If a patient on a beta-blocker has an anaphylactic reaction to the extract, the beta-blocker will prevent epinephrine from working effectively, which can lead to a fatal outcome.

• ACE Inhibitors (e.g., Lisinopril): Some studies suggest that patients taking ACE inhibitors may be at an increased risk for more severe systemic reactions to allergenic extracts.
• Tricyclic Antidepressants (TCAs) and MAOIs: These medications can potentiate the effects of epinephrine, which might be problematic if epinephrine must be administered to treat an allergic reaction. This can lead to severe hypertension or cardiac arrhythmias.

• Antihistamines (e.g., Loratadine, Cetirizine): These medications do not interfere with immunotherapy itself, but they MUST be stopped 3 to 7 days before diagnostic skin testing. Antihistamines suppress the skin's response to the allergen, leading to a false-negative result.
• Systemic Corticosteroids: High doses of oral steroids (like prednisone) may suppress the immune response to the extract, potentially reducing its long-term effectiveness. However, low-dose inhaled steroids for asthma are generally acceptable and necessary for safety.

• Cross-Reactive Foods: Patients allergic to Achillea Millefolium (Yarrow) may experience 'Oral Allergy Syndrome' when eating certain foods in the same family or with similar proteins. This may include chamomile, sunflower seeds, or artichokes. While these foods don't interact with the injection directly, they can increase the overall 'allergic load' on the body.
• Caffeine: Excessive caffeine intake before an injection might increase heart rate and jitteriness, making it harder to distinguish between caffeine effects and the early signs of a systemic reaction.

• Chamomile and Echinacea: These herbs are in the same botanical family (Asteraceae) as Yarrow. Taking these supplements while receiving Yarrow immunotherapy might increase the risk of an allergic flare-up.
• St. John's Wort: While no direct interaction is documented, St. John's Wort can affect the metabolism of many drugs and should be discussed with an immunologist.

• Skin Prick Tests: As mentioned, the extract is used for testing, but other medications can interfere with the results.
• Total IgE Levels: Immunotherapy may cause a transient rise in total IgE levels before they eventually decline over years of treatment. This should be interpreted carefully by the clinician.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Achillea Millefolium Whole must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients with a forced expiratory volume in 1 second (FEV1) consistently below 80% of predicted values are at high risk for fatal bronchospasm during immunotherapy.
• Recent Myocardial Infarction (Heart Attack): Any patient who has had a heart attack or unstable angina within the last 3-6 months should not start immunotherapy due to the cardiac stress of potential anaphylaxis.
• History of Severe Anaphylaxis to this Specific Extract: If a patient has previously had a near-fatal reaction to Achillea millefolium extract, the risk of continuing usually outweighs the benefit.
• Beta-Blocker Therapy: As noted previously, the inability to treat anaphylaxis with epinephrine makes this an absolute contraindication in many clinical guidelines.

Conditions requiring careful risk-benefit analysis include:

• Autoimmune Disorders: There is a theoretical concern that stimulating the immune system with allergenic extracts could worsen conditions like systemic lupus erythematosus (SLE) or rheumatoid arthritis.
• Malignancy: Patients with active cancer are generally not started on immunotherapy, though those in remission may be candidates.
• Pregnancy (Starting Therapy): It is generally recommended not to start immunotherapy during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia (low oxygen to the baby).
• Severe Atopic Dermatitis: If the skin is too inflamed, it may be impossible to accurately perform or read diagnostic skin tests.

Patients should be aware of cross-sensitivity within the Asteraceae family. If you are severely allergic to yarrow, you may also react to:

• Ragweed (Ambrosia)
• Daisies and Chrysanthemums
• Marigolds
• Dandelions
• Sunflowers

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Achillea Millefolium Whole.

Pregnancy Category C. There are no adequate and well-controlled studies of Achillea Millefolium Whole in pregnant women.

• Risk Summary: The primary risk to the fetus is maternal anaphylaxis, which can lead to placental hypoperfusion and fetal distress or death.
• Clinical Considerations: Most allergists will not initiate (start) immunotherapy during pregnancy. However, if a patient is already on a stable maintenance dose and is tolerating it well, the healthcare provider may choose to continue the therapy at the same or a slightly reduced dose, as the risk of a reaction is lower during maintenance than during the build-up phase.

It is not known whether the allergenic components of Achillea Millefolium Whole are excreted in human milk. However, because these are proteins that are digested in the infant's gastrointestinal tract, they are unlikely to cause harm. The consensus is that breastfeeding is not a contraindication to receiving allergy shots.

• Approved Age: Immunotherapy is generally considered safe for children aged 5 years and older.
• Safety: Children are at the same risk for systemic reactions as adults. The decision to treat a child depends on the severity of their symptoms and their ability to cooperate with the injection and observation process.
• Growth Effects: There is no evidence that allergenic extracts interfere with normal growth and development.

• Cardiovascular Risk: Patients over 65 are more likely to have underlying heart disease, which increases the risk of complications from anaphylaxis.
• Polypharmacy: Elderly patients are often on multiple medications (like ACE inhibitors or beta-blockers) that can interact with the extract or its emergency treatment.
• Dosing: A slower build-up phase is often recommended for older adults.

Patients with chronic kidney disease (CKD) can generally receive Achillea Millefolium Whole. However, if they are on dialysis, the timing of the injection should be coordinated so it does not occur immediately before or after a dialysis session, as blood pressure fluctuations are common during those times.

There are no specific restrictions for patients with liver disease. Since the extract is not metabolized by the liver's cytochrome P450 system, hepatic impairment does not affect the 'clearance' of the allergen in the traditional sense.

> Important: Special populations require individualized medical assessment to ensure the benefits of immunotherapy outweigh the potential risks.

Achillea Millefolium Whole acts as an immunotherapeutic agent. The extract contains a variety of proteins, including sesquiterpene lactones and flavonoids, which serve as antigens. Upon subcutaneous administration, these antigens are captured by antigen-presenting cells (APCs), such as dendritic cells. These cells migrate to the lymph nodes and present the antigens to naive T-cells. In an allergic individual, this normally produces a Th2 response. Immunotherapy induces 'immune deviation,' shifting the response toward Th1 and T-regulatory cells. This leads to the production of IL-10, which suppresses IgE production and increases the production of IgG4 (blocking antibodies).

• Dose-Response: There is a clear dose-response relationship in immunotherapy; higher doses (within the maintenance range) generally lead to better long-term symptom control.
• Time to Onset: Diagnostic skin test results appear within 15-20 minutes. Therapeutic effects (symptom reduction) typically take 3 to 6 months to become noticeable.
• Duration of Effect: The benefits of a full 3-to-5-year course can last for several years after the treatment is stopped.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous local interaction) |

| Protein Binding | N/A (Biological proteins) |

| Half-life | Days (Proteins); Years (Immunological memory) |

| Tmax | 30-60 minutes (Systemic absorption of allergens) |

| Metabolism | Local and systemic proteolysis |

| Excretion | Renal (as peptide fragments) |

• Composition: A complex aqueous extract containing proteins, glycoproteins, and polysaccharides.
• Source: Achillea millefolium (Whole plant).
• Solubility: Soluble in aqueous buffers; often stabilized with 50% glycerin for diagnostic use.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various allergenic proteins.

Achillea Millefolium Whole is classified as a Non-Standardized Plant Allergenic Extract. It belongs to the therapeutic category of Allergenic Extracts or Biologicals for Immunotherapy. It is related to other Asteraceae extracts like Ragweed (Ambrosia) and Mugwort (Artemisia).